Cover Image
Market Research Report

Otitis Media - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 232857
Published Content info 71 Pages
Delivery time: 1-2 business days
Price
Back to Top
Otitis Media - Pipeline Review, H2 2019
Published: September 23, 2019 Content info: 71 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Pipeline Review, H2 2019, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.

Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11394IDB

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Otitis Media - Overview
  • Otitis Media - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Otitis Media - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Otitis Media - Companies Involved in Therapeutics Development
  • Lee's Pharmaceutical Holdings Ltd
  • Madam Therapeutics BV
  • Merck & Co Inc
  • MerLion Pharmaceuticals Pte Ltd
  • Novus Therapeutics Inc
  • Yuhan Corp
  • Otitis Media - Drug Profiles
  • (cholesteryl palmitate + colfosceril palmitate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (dexamethasone + piperacillin + tazobactam) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aspoxicillin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs for Otitis Media - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ENT-103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • finafloxacin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OR-404IT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pazufloxacin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PCL-1440 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pneumococcal (13-valent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pneumococcal (23-valent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Otitis Media - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • solithromycin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tebipenem pivoxil - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Otitis Media - Dormant Projects
  • Otitis Media - Product Development Milestones
  • Featured News & Press Releases
  • Jun 10, 2019: Novus Therapeutics to present OP0201 data at the 20th international symposium on recent advances in otitis media
  • Apr 23, 2019: Novus' Phase I trials of otitis media drug meet primary objective
  • Feb 20, 2019: Novus Therapeutics begins dosing in otitis media drug trial
  • Feb 11, 2019: Novus Therapeutics doses first subjects in phase 1 pharmacodynamics study of OP0201
  • Jan 30, 2019: Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials
  • Jan 10, 2019: Novus doses first patient in Phase I trial of OP0201
  • Dec 04, 2018: Novus Therapeutics announces formation of Scientific Advisory Board
  • Nov 28, 2018: Novus Therapeutics doses first subject in Phase I trial of OP0201
  • Jun 19, 2018: Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media
  • Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media
  • Oct 29, 2012: Study Suggests New Way to Prevent Recurrent Ear Infections
  • Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Finafloxacin For Treatment Of Acute Otitis Media
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Otitis Media, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Otitis Media - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2019
  • Otitis Media - Pipeline by Madam Therapeutics BV, H2 2019
  • Otitis Media - Pipeline by Merck & Co Inc, H2 2019
  • Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2019
  • Otitis Media - Pipeline by Novus Therapeutics Inc, H2 2019
  • Otitis Media - Pipeline by Yuhan Corp, H2 2019
  • Otitis Media - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Otitis Media, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top